论文部分内容阅读
目的探讨卵巢癌患者外周血循环肿瘤细胞(CTC)的水平及其与临床病理参数及预后的关系。方法收集2010年1月-2014年1月在青岛经济技术开发区第一人民医院接受诊治的卵巢癌患者46例作为卵巢癌组,同时收集卵巢良性囊肿患者60例作为对照组。空腹时抽取静脉血5 ml,采用Can Patrol法检测患者外周血中CTC,并分析其与临床病理参数及预后的关系。结果对照组均未检测出外周血CTC,卵巢癌组外周血CTC阳性34例,阳性率为73.91%;卵巢癌患者外周血CTC阳性率与临床分期有关(χ~2=4.041,P=0.021),与患者年龄、病理组织学分型、病理分级无显著性差异(P>0.05);34例CTC表达阳性患者,无进展生存18例,生存率为52.94%,11例CTC阴性表达患者,无进展生存9例,生存率为81.81%,两者比较,差异有统计学意义(χ~2=5.011,P=0.026)。结论卵巢癌患者外周血中CTC水平较高,与临床分期密切相关,且CTC阳性患者无进展生存率较CTC阴性的患者显著缩短,这显示CTC可以作为一种新的生物标志物用于卵巢癌的检测、治疗监测以及预后评估。
Objective To investigate the level of circulating tumor cells (CTCs) in patients with ovarian cancer and its relationship with clinicopathological parameters and prognosis. Methods A total of 46 patients with ovarian cancer undergoing diagnosis and treatment in the First People’s Hospital of Qingdao Economic and Technological Development Zone from January 2010 to January 2014 were selected as ovarian cancer patients and 60 patients with benign ovarian cysts as control group. Blood samples were taken from 5 ml of fasting blood and Can Patrol method was used to detect CTC in peripheral blood and the relationship between CTC and clinicopathological parameters and prognosis was analyzed. Results CTC was not detected in the control group. CTC was positive in peripheral blood of ovarian cancer patients (34.9%), the positive rate was 73.91%. The positive rate of CTC in peripheral blood of ovarian cancer patients was related to clinical stage (χ ~ 2 = 4.041, P = 0.021) (P> 0.05). There were 18 cases with progression-free survival in 34 patients with positive CTC and the survival rate was 52.94%. There was no progress in 11 patients with CTC negative expression There were 9 cases surviving, the survival rate was 81.81%. The difference was statistically significant (χ ~ 2 = 5.011, P = 0.026). Conclusions CTC levels in peripheral blood of patients with ovarian cancer are high and closely related to clinical stage, and the progression-free survival rate of patients with CTC positive is significantly shorter than that of patients with negative CTC, indicating that CTC can be used as a new biomarker for ovarian cancer Testing, treatment monitoring, and prognosis.